Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immediate Shared Diagnostics Approach Recommended for Ebola Outbreak

By LabMedica International staff writers
Posted on 20 May 2014
A NIH scientist has emphasized the need for an immediate, "real-time" global data sharing and regional diagnostic approach to improve the world's response to the recent Ebolavirus outbreak underway among the peoples of West Africa.

The origin, locations, and natural habitat of Ebolavirus remain unknown. More...
On the basis of available evidence and the nature of similar viruses, researchers suggest that the virus is zoonotic and normally maintained in a host native to Africa. An absence of effective intervention strategies makes diagnosis a key element in response. But without access to modern molecular techniques, early diagnosis of Ebola hemorrhagic fevers can be particularly difficult because early symptoms are often similar to other infectious diseases, such as malaria and typhoid fever.

In an invited perspective article in the New England Journal of Medicine (NEJM), published May 7, 2014, Ebola expert Heinz Feldmann, MD, PhD, from the National Institute of Allergy and Infectious Diseases (NIAID; Bethesda, MD, USA) of the National Institutes of Health (NIH), emphasizes the need for scientists everywhere to make their relevant data available in real-time to colleagues involved in the public health response to a given outbreak. He cites past responses to influenza and SARS (severe acute respiratory syndrome) outbreaks as successful examples of global information sharing. Rapid diagnoses are key to controlling outbreaks of such deadly pathogens for which no therapies are available. The immediate availability of viral gene sequencing data, for example, can reduce waiting times for test results and help to determine whether established test methods will work or fail.

Dr. Feldmann, chief of NIAID’s Laboratory of Virology, conducts research on Ebola and other hemorrhagic fever viruses. Among other suggestions, he recommends that medical and public health staff in and near locations known to be endemic for Ebola be trained to assess infection risks and diagnose disease. Enhancing the capabilities of local laboratory workers would make test results available more rapidly by eliminating the need to ship samples to distant reference laboratories.

Dr. Feldmann and his NIAID colleague David Safronetz, PhD, explored this regional diagnostic approach while working with Malian health researchers and officials in April, after Mali reported 12 suspected Ebola cases. The NIAID group worked at the International Center for Excellence in Research, a partnership between NIAID and Mali’s University of Bamako, where they observed isolation procedures and showed local physicians how to handle Ebola specimens and test for disease. In this case, all the suspected cases in Mali tested negative.

Related Links:

National Institute of Allergy and Infectious Diseases (NIAID)



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.